Forest Labs News

Ironwood Pharmaceuticals Inc. has priced a public stock offering aimed at bringing in just under $80 million to support the expected launch of its irritable bowel syndrome drug candidate, linaclotide.

Forest Laboratories, Inc. and partner Gedeon Richter recently presented positive top-line results on their antipsychotic candidate, cariprazine .

Danish drugmaker Lundbeck forecast declining sales and operating profits this year after fourth-quarter profit missed analysts' forecasts and the group faces a patent expiry on its key antidepressant.

NEW YORK & BUDAPEST, Hungary -- -- Forest Laboratories, Inc. and Gedeon Richter Plc.

Adeona Appoints C. Evan Ballantyne CFO : Ann Arbor-based Adeona Pharmaceuticals Inc.

Anglo Pacific Group announced that it has agreed with Red Rock Resources to acquire 50% of a 1.5% gross revenue iron-ore royalty in the Mount Ida project in Western Australia from the miner for $14 million.

Forest Laboratories 's stock had its "hold" rating reaffirmed by analysts at Needham & Company in a research report issued to clients and investors on Wednesday.

Forest Laboratories, Inc. reported earnings per share of $1.04 in the third quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.00. Third quarter fiscal 2012 earnings, however, came in below the year-earlier earnings of $1.34. Despite an increase in revenues, higher costs led to the year-over-year decline in earnings.

Francis I. Perier - Chief Financial Officer, Executive Vice President of Finance & Administration and Member of Disclosure, Legal Compliance & Risk Management Committee Marco Taglietti - Senior Vice President of Research & Development, Member of Disclosure, Legal Compliance & Risk Management Committee and President of Forest Research Institute Good ... (more)

The 10-second takeaway For the quarter ended Dec. 31 , Forest Laboratories beat expectations on revenues and beat expectations on earnings per share.

S&P 500 component Forest Laboratories Inc. reported its results for the third quarter.

Forest Laboratories, Inc. , an international pharmaceutical manufacturer and marketer, today announced that reported earnings per share were $1.04 in the third quarter of fiscal 2012.

Stocks are set to rally Tuesday as investors look to corporate profits as earnings season picks up and Chinese data fuel the belief the government may move to stimulate growth.

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, January 17th 2012 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports.